Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles do not contract normally and not able to pump blood in a normal manner. Furthermore, heart becomes weak, which can ultimately lead to heart failure. Common symptoms of heart failure include fatigue, edema in ankles, legs, feet, veins in the neck and abdomen. There are various reasons for the cause of dilated cardiomyopathy such as viral infection, uncontrolled blood pressure, excessive amount of alcohol, and problem with the heart valve. There is no proper drug for the treatment of DCM, healthcare professionals use congestive heart failure drugs for treatment. Dilated cardiomyopathy majorly occurs in the age group of 20-60 years and rarely among children. It is easily diagnosed by normal chest X-ray and echocardiogram, and at times using cardiac MRI. There are certain implantable devices such as Implantable Cardioverter Defibrillator (ICD) and pacemaker which is implanted in the high risk patient body to maintain the proper rhythmic function of the heart and keeps the track of heart rate to avoid the chances of cardiac arrest. As per British Heart Foundation, in 2015, there are around 25,000 implants of pacemaker implanted every year in the UK.

Rise in congestive heart failure fuels the growth of dilated cardiomyopathy market

Globally increase in the congestive heart failure cases, which leads to the increase in dilated cardiomyopathy cases. As per American Heart Association, in 2016, there were around 5.7 million adults in the U.S. who suffered from heart failure. However, there is no drug approved by FDA for the treatment of dilated cardiomyopathy furthermore, companies are investing in research and development of new drugs such as ARRY-797 and Ixmyelocel-T, which is expected to support the growth of dilated cardiomyopathy market. Major challenges for DCM market are increased use of defibrillators, pacemaker, and lack of proper drugs.

Developed regions are major growth engine of dilated cardiomyopathy market

Dilated cardiomyopathy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. North America has shown significant growth in DCM market due to increase in congestive heart failure cases. Europe is the second largest market of DCM as per, European Heart Network 2017 report, there are around 3.9 million deaths caused by cardiovascular disease in Europe and more than 1.8 million deaths in the Europe Union. Asia Pacific is the third largest market and expected to grow at a higher rate due to increased awareness of cardiovascular disease and demand of generic drugs is expected to support the growth of DCM market.

Key players of dilated cardiomyopathy market

There are various players in the DCM market present across the globe, which contributes to the DCM market. Some key players are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Array BioPharma, AstraZeneca, GlaxoSmithKline Plc., and Sanofi.

Key Developments:

In August 2019, MyoKardia, Inc., launched the 2^nd Annual Myoseeds Research Grant Program in order to promote independent research in biology and to understand the mechanism of cardiomyopathies and its treatment.
In 2019, the DCM Foundation in Ohio, announced the launch of a website to increase awareness for dilated cardiomyopathy (DCM) and to educate the patients and their loved ones on the for the management of the heart condition. Many causes of DCM have been reported and approximately 1 in 250 people have DCM. Many patients have been reported to suffer from Idiopathic DCM, meaning, DCM due to unknown cause. Hence, genetic factors are considered to play a key role in idiopathic DCM, hence, in order to find this relation, DCM foundation has collaborated with DCM Research Project which is funded by National Institute of Health. The findings are always published on the DCM website.
In 2018, Myokardia, Inc., collaborated with 23andMe, a DNA testing and Analysis Company located in California, in order to conduct advanced research for the patients suffering from Hypertrophic Myopathy (HCM) and DCM, to improve the quality of life of the patients as well as to provide effective treatment to the patients.
In 2017, Phosphorus, Inc., launched advanced genetic tests for the diagnosis of DCM due to the inherited conditions which are associated with early-onset of the cardiovascular disease and sudden death.

Global Dilated Cardiomyopathy Market Taxonomy:

By Drugs